CAMBRIDGE, Mass., Nov. 14, 2019 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a precision therapy
company focused on genomically defined cancers, rare diseases and
cancer immunotherapy, today announced that Jeff Albers, Blueprint Medicines' Chief
Executive Officer, will present a company overview at the Jefferies
2019 London Healthcare Conference in London, United Kingdom on Thursday, November 21, 2019 at 4:00 p.m. GMT (11:00 a.m.
ET).
A live webcast of the presentation will be available by visiting
the Investors & Media section of Blueprint
Medicines' website at http://ir.blueprintmedicines.com. A
replay of the webcast will be archived on Blueprint
Medicines' website for 30 days following the presentation.
About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving
to improve human health. With a focus on genomically defined
cancers, rare diseases and cancer immunotherapy, we are developing
transformational medicines rooted in our leading expertise in
protein kinases, which are proven drivers of disease. Our uniquely
targeted, scalable approach empowers the rapid design and
development of new treatments and increases the likelihood of
clinical success. We are currently advancing three investigational
medicines in clinical development, along with multiple research
programs. For more information,
visit www.BlueprintMedicines.com and follow us
on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-jefferies-2019-london-healthcare-conference-300957672.html
SOURCE Blueprint Medicines